We expect continued momentum in 2Q:F26 muted by the divestiture of the Healthcare business, which creates a difficult comparison with 2Q:F25. Results should normalize in 3Q:F26 and be helped by the wind down of a non-profitable supply agreement by February. We think the company has reached an inflection point. We expect to see continuous year-over-year revenue growth aided by continued demand from semiconductors and a pick-up in GES, driven by orders in the wind turbine market. Other projects in the pipeline should come to fruition in upcoming quarters. The company continues to work on expanding its partnership network from delivering components to engineering solutions, which should help deepen its engagement. We expect continued positive operating cash flow in 2Q:F25. RELL maintained a strong cash balance of $35.7 million at the end of 1Q:F26 and remains debt free. The $0.24 annualized dividend, which yields 2.2%, is protected, in our opinion. We apply a 24x multiple to our F2027 EPS estimate of $0.55 to derive our $13 price target. Our 24x multiple is higher than the 22x two-year historical average, which we think is appropriate given the company's improved balance sheet and growth outlook. Our moderate risk assessment is supported by the company's debt-free balance sheet, blue-chip customer base, profit growth potential, strong backlog and free cash flow.